Discover
OKYO
OKYO Pharma Limited
1.44
2 x 1.43
1 x 1.46
bid
ask
+
0.07
5.11%
1 @ 04:00 PM
1.50 +0.06 (4.17%)
| Ytd | -30.43% | |
| 1y | -48.94% |
1.38
day range
1.49
1.34
52 week range
3.35
| Open | 1.40 | Prev Close | 1.37 | Low | 1.38 | High | 1.49 | Mkt Cap | 55.25M |
| Vol | 184.44K | Avg Vol | 89.19K | EPS | -0.05 | P/E | -28.69 | Forward P/E | N/A |
| Beta | 0.06 | Short Ratio | 4.64 | Inst. Own | 2.96% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 1.59 | 200-d Avg | 1.88 | 1yr Est | 7.00 |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-10-24 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-10-16 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-08-27 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-07-12 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-07-11 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-03-22 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Profile
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead clinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease; in phase 1 clinical trial for the treatment of neuropathic corneal pain; and is in preclinical trial to treat allergic conjunctivitis and uveitis. The company is also developing OK-201, which is in preclinical trial for the treatment of dry eye disease and neuropathic chronic pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Barclays Plc | 961.00K | 1.02M | 2.84% |
| 2024-09-29 | Cerity Partners LLC | 12.81K | 13.58K | 0.04% |
| 2024-09-29 | Geode Capital Management, LLC | 12.09K | 12.82K | 0.04% |
| 2024-09-29 | Citadel Advisors Llc | 14.88K | 15.77K | 0.04% |
| 2024-09-29 | UBS Group AG | 525.00 | 556.00 | 0.00% |
| 2024-09-29 | Continuum Advisory, Llc | 50.00 | 52.00 | 0.00% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-10-30 | Fidelity NASDAQ Composite Index Fund | 12.09K | 12.82K | 0.04% |